-
1
-
-
77951573241
-
Antibodies to watch in 2010
-
Reichert J.M. Antibodies to watch in 2010. MAbs 2010, 2:84-100.
-
(2010)
MAbs
, vol.2
, pp. 84-100
-
-
Reichert, J.M.1
-
2
-
-
20044375603
-
Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro
-
Wang Y., Fei D., Vanderlaan M., Song A. Biological activity of bevacizumab, a humanized anti-VEGF antibody in vitro. Angiogenesis 2004, 7:335-345.
-
(2004)
Angiogenesis
, vol.7
, pp. 335-345
-
-
Wang, Y.1
Fei, D.2
Vanderlaan, M.3
Song, A.4
-
3
-
-
77950263939
-
Review of tocilizumab in the treatment of rheumatoid arthritis
-
Okuda Y. Review of tocilizumab in the treatment of rheumatoid arthritis. Biologics 2008, 2:75-82.
-
(2008)
Biologics
, vol.2
, pp. 75-82
-
-
Okuda, Y.1
-
4
-
-
33750622479
-
Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab
-
Bowles J.A., Wang S.Y., Link B.K., Allan B., Beuerlein G., Campbell M.A., Marquis D., Ondek B., Wooldridge J.E., Smith B.J., Breitmeyer J.B., Weiner G.J. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood 2006, 108:2648-2654.
-
(2006)
Blood
, vol.108
, pp. 2648-2654
-
-
Bowles, J.A.1
Wang, S.Y.2
Link, B.K.3
Allan, B.4
Beuerlein, G.5
Campbell, M.A.6
Marquis, D.7
Ondek, B.8
Wooldridge, J.E.9
Smith, B.J.10
Breitmeyer, J.B.11
Weiner, G.J.12
-
5
-
-
0042346042
-
Complement activation determines the therapeutic activity of rituximab in vivo
-
Di Gaetano N., Cittera E., Nota R., Vecchi A., Grieco V., Scanziani E., Botto M., Introna M., Golay J. Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. 2003, 171:1581-1587.
-
(2003)
J. Immunol.
, vol.171
, pp. 1581-1587
-
-
Di Gaetano, N.1
Cittera, E.2
Nota, R.3
Vecchi, A.4
Grieco, V.5
Scanziani, E.6
Botto, M.7
Introna, M.8
Golay, J.9
-
6
-
-
0036464611
-
The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction
-
Byrd J.C., Kitada S., Flinn I.W., Aron J.L., Pearson M., Lucas D., Reed J.C. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood 2002, 99:1038-1043.
-
(2002)
Blood
, vol.99
, pp. 1038-1043
-
-
Byrd, J.C.1
Kitada, S.2
Flinn, I.W.3
Aron, J.L.4
Pearson, M.5
Lucas, D.6
Reed, J.C.7
-
7
-
-
0036464719
-
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
-
Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., Watier H. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 2002, 99:754-758.
-
(2002)
Blood
, vol.99
, pp. 754-758
-
-
Cartron, G.1
Dacheux, L.2
Salles, G.3
Solal-Celigny, P.4
Bardos, P.5
Colombat, P.6
Watier, H.7
-
8
-
-
0642373290
-
Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma
-
Weng W.K., Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol. 2003, 21:3940-3947.
-
(2003)
J. Clin. Oncol.
, vol.21
, pp. 3940-3947
-
-
Weng, W.K.1
Levy, R.2
-
9
-
-
4444372733
-
Other 5 authors Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2
-
Gennari R., Menard S., Fagnoni F., Ponchio L., Scelsi M., Tagliabue E., Castiglioni F., Villani L., Magalotti C., Gibelli N., other 5 authors Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2. Clin. Cancer Res. 2004, 10:5650-5655.
-
(2004)
Clin. Cancer Res.
, vol.10
, pp. 5650-5655
-
-
Gennari, R.1
Menard, S.2
Fagnoni, F.3
Ponchio, L.4
Scelsi, M.5
Tagliabue, E.6
Castiglioni, F.7
Villani, L.8
Magalotti, C.9
Gibelli, N.10
-
10
-
-
34548509226
-
Other 3 authors FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab
-
Zhang W., Gordon M., Schultheis A.M., Yang D.Y., Nagashima F., Azuma M., Chang H.M., Borucka E., Lurje G., Sherrod A.E., other 3 authors FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J. Clin. Oncol. 2007, 25:3712-3718.
-
(2007)
J. Clin. Oncol.
, vol.25
, pp. 3712-3718
-
-
Zhang, W.1
Gordon, M.2
Schultheis, A.M.3
Yang, D.Y.4
Nagashima, F.5
Azuma, M.6
Chang, H.M.7
Borucka, E.8
Lurje, G.9
Sherrod, A.E.10
-
11
-
-
54249100952
-
Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia
-
Horton H.M., Bernett M.J., Pong E., Peipp M., Karki S., Chu S.Y., Richards J.O., Vostiar I., Joyce P.F., Repp R., Desjarlais J.R., Zhukovsky E.A. Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res. 2008, 68:8049-8057.
-
(2008)
Cancer Res.
, vol.68
, pp. 8049-8057
-
-
Horton, H.M.1
Bernett, M.J.2
Pong, E.3
Peipp, M.4
Karki, S.5
Chu, S.Y.6
Richards, J.O.7
Vostiar, I.8
Joyce, P.F.9
Repp, R.10
Desjarlais, J.R.11
Zhukovsky, E.A.12
-
12
-
-
0037306893
-
In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas
-
Manches O., Lui G., Chaperot L., Gressin R., Molens J.P., Jacob M.C., Sotto J.J., Leroux D., Bensa J.C., Plumas J. In vitro mechanisms of action of rituximab on primary non-Hodgkin lymphomas. Blood 2003, 101:949-954.
-
(2003)
Blood
, vol.101
, pp. 949-954
-
-
Manches, O.1
Lui, G.2
Chaperot, L.3
Gressin, R.4
Molens, J.P.5
Jacob, M.C.6
Sotto, J.J.7
Leroux, D.8
Bensa, J.C.9
Plumas, J.10
-
13
-
-
39649122877
-
Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30
-
Oflazoglu E., Stone I.J., Gordon K.A., Grewal I.S., van Rooijen N., Law C.L., Gerber H.P. Macrophages contribute to the antitumor activity of the anti-CD30 antibody SGN-30. Blood 2007, 110:4370-4372.
-
(2007)
Blood
, vol.110
, pp. 4370-4372
-
-
Oflazoglu, E.1
Stone, I.J.2
Gordon, K.A.3
Grewal, I.S.4
van Rooijen, N.5
Law, C.L.6
Gerber, H.P.7
-
14
-
-
33846894105
-
Other 3 authors Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities
-
McEarchern J.A., Oflazoglu E., Francisco L., McDonagh C.F., Gordon K.A., Stone I., Klussman K., Turcott E., van Rooijen N., Carter P., other 3 authors Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood 2007, 109:1185-1192.
-
(2007)
Blood
, vol.109
, pp. 1185-1192
-
-
McEarchern, J.A.1
Oflazoglu, E.2
Francisco, L.3
McDonagh, C.F.4
Gordon, K.A.5
Stone, I.6
Klussman, K.7
Turcott, E.8
van Rooijen, N.9
Carter, P.10
-
15
-
-
0036676975
-
Roles of Fc receptors in autoimmunity
-
Takai T. Roles of Fc receptors in autoimmunity. Nat. Rev. Immunol. 2002, 2:580-592.
-
(2002)
Nat. Rev. Immunol.
, vol.2
, pp. 580-592
-
-
Takai, T.1
-
16
-
-
0025802963
-
Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages
-
Munn D.H., McBride M., Cheung N.K. Role of low-affinity Fc receptors in antibody-dependent tumor cell phagocytosis by human monocyte-derived macrophages. Cancer Res. 1991, 51:1117-1123.
-
(1991)
Cancer Res.
, vol.51
, pp. 1117-1123
-
-
Munn, D.H.1
McBride, M.2
Cheung, N.K.3
-
17
-
-
53349120501
-
Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells
-
Richards J.O., Karki S., Lazar G.A., Chen H., Dang W., Desjarlais J.R. Optimization of antibody binding to FcgammaRIIa enhances macrophage phagocytosis of tumor cells. Mol. Cancer Ther. 2008, 7:2517-2527.
-
(2008)
Mol. Cancer Ther.
, vol.7
, pp. 2517-2527
-
-
Richards, J.O.1
Karki, S.2
Lazar, G.A.3
Chen, H.4
Dang, W.5
Desjarlais, J.R.6
-
18
-
-
76249090327
-
Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A
-
Shashidharamurthy R., Zhang F., Amano A., Kamat A., Panchanathan R., Ezekwudo D., Zhu C., Selvaraj P. Dynamics of the interaction of human IgG subtype immune complexes with cells expressing R and H allelic forms of a low-affinity Fc gamma receptor CD32A. J. Immunol. 2009, 183:8216-8224.
-
(2009)
J. Immunol.
, vol.183
, pp. 8216-8224
-
-
Shashidharamurthy, R.1
Zhang, F.2
Amano, A.3
Kamat, A.4
Panchanathan, R.5
Ezekwudo, D.6
Zhu, C.7
Selvaraj, P.8
-
19
-
-
41849090725
-
Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity
-
Nagashima H., Tezuka T., Tsuchida W., Maeda H., Kohroki J., Masuho Y. Tandemly repeated Fc domain augments binding avidities of antibodies for Fcgamma receptors, resulting in enhanced antibody-dependent cellular cytotoxicity. Mol. Immunol. 2008, 45:2752-2763.
-
(2008)
Mol. Immunol.
, vol.45
, pp. 2752-2763
-
-
Nagashima, H.1
Tezuka, T.2
Tsuchida, W.3
Maeda, H.4
Kohroki, J.5
Masuho, Y.6
-
20
-
-
33646740982
-
Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa
-
Iida S., Misaka H., Inoue M., Shibata M., Nakano R., Yamane-Ohnuki N., Wakitani M., Yano K., Shitara K., Satoh M. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin. Cancer Res. 2006, 12:2879-2887.
-
(2006)
Clin. Cancer Res.
, vol.12
, pp. 2879-2887
-
-
Iida, S.1
Misaka, H.2
Inoue, M.3
Shibata, M.4
Nakano, R.5
Yamane-Ohnuki, N.6
Wakitani, M.7
Yano, K.8
Shitara, K.9
Satoh, M.10
-
21
-
-
0032753490
-
Modular components of phagocytosis
-
Greenberg S. Modular components of phagocytosis. J. Leukoc. Biol. 1999, 66:712-717.
-
(1999)
J. Leukoc. Biol.
, vol.66
, pp. 712-717
-
-
Greenberg, S.1
-
22
-
-
0028962899
-
Molecular dissection of Fc gamma receptor-mediated phagocytosis
-
Indik Z.K., Park J.G., Hunter S., Mantaring M., Schreiber A.D. Molecular dissection of Fc gamma receptor-mediated phagocytosis. Immunol. Lett. 1995, 44:133-138.
-
(1995)
Immunol. Lett.
, vol.44
, pp. 133-138
-
-
Indik, Z.K.1
Park, J.G.2
Hunter, S.3
Mantaring, M.4
Schreiber, A.D.5
-
23
-
-
0036025336
-
Fcgamma receptor-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro
-
Tebo A.E., Kremsner P.G., Luty A.J. Fcgamma receptor-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro. Clin. Exp. Immunol. 2002, 130:300-306.
-
(2002)
Clin. Exp. Immunol.
, vol.130
, pp. 300-306
-
-
Tebo, A.E.1
Kremsner, P.G.2
Luty, A.J.3
-
24
-
-
0033766761
-
Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor
-
Wallace P.K., Romet-Lemonne J.L., Chokri M., Kasper L.H., Fanger M.W., Fadul C.E. Production of macrophage-activated killer cells for targeting of glioblastoma cells with bispecific antibody to FcgammaRI and the epidermal growth factor receptor. Cancer Immunol. Immunother. 2000, 49:493-503.
-
(2000)
Cancer Immunol. Immunother.
, vol.49
, pp. 493-503
-
-
Wallace, P.K.1
Romet-Lemonne, J.L.2
Chokri, M.3
Kasper, L.H.4
Fanger, M.W.5
Fadul, C.E.6
-
25
-
-
77951909169
-
Differential recruitment of activating and inhibitory Fc gamma RII during phagocytosis
-
Syam S., Mero P., Pham T., McIntosh C.A., Bruhns P., Booth J.W. Differential recruitment of activating and inhibitory Fc gamma RII during phagocytosis. J. Immunol. 2010, 184:2966-2973.
-
(2010)
J. Immunol.
, vol.184
, pp. 2966-2973
-
-
Syam, S.1
Mero, P.2
Pham, T.3
McIntosh, C.A.4
Bruhns, P.5
Booth, J.W.6
|